ID   MCF-7/AnaR-1
AC   CVCL_5A09
SY   MCF7/AnaR-1; AnaR-1
DR   ECACC; 16022516
DR   Wikidata; Q54904353
DR   Ximbio; 152551
RX   PubMed=25625755;
CC   Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole.
CC   Sequence variation: Homozygous for CDKN2A deletion (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (ClinVar=VCV000013655) (from parent cell line).
CC   Derived from metastatic site: Pleural effusion.
DI   NCIt; C4194; Invasive ductal carcinoma, not otherwise specified
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1D47 ! MCF-7/S0.5
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 02-07-20; Version: 7
RX   PubMed=25625755; DOI=10.3892/ijo.2015.2850;
RA   Hole S., Pedersen A.M., Hansen S.K., Lundqvist J., Yde C.W.,
RA   Lykkesfeldt A.E.;
RT   "New cell culture model for aromatase inhibitor-resistant breast
RT   cancer shows sensitivity to fulvestrant treatment and cross-resistance
RT   between letrozole and exemestane.";
RL   Int. J. Oncol. 46:1481-1490(2015).